此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

尿道周围与阴道内雌激素预防复发性尿路感染 (TAPER)

2026年8月31日 更新者:Stephanie Wang Zuo

尿道周围与阴道内雌激素预防复发性尿路感染:TAPER(应用阴道雌激素预防复发性尿路感染的技术)试验

Due to rising antibiotic resistance, there has been a focus on non-antibiotic prophylactic measures for postmenopausal patients with recurrent urinary tract infections (rUTI), one of which is the safe and efficacious option of vaginal estrogen therapy. Standard application of vaginal estrogen cream entails intravaginal application of the cream twice a week, but some providers counsel patients with rUTI to apply a small, pea-sized amount to the periurethral area. This ideally reduces the amount of vaginal estrogen used while attaining a similar effect. However, to date, there is no data to prove that the periurethral technique of application is similar or non-inferior to intravaginal application in preventing UTI.

研究概览

研究类型

介入性

注册 (实际的)

114

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Pennsylvania
      • Cranberry Township、Pennsylvania、美国、16066
        • UPMC Lemieux Sports Complex
      • Erie、Pennsylvania、美国、16550
        • UPMC Hamot
      • Pittsburgh、Pennsylvania、美国、15213
        • University of Pittsburgh Medical Center-Magee Womens Hospital
      • Pittsburgh、Pennsylvania、美国、15237
        • UPMC Passavant-McCandless

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Postmenopausal (definition: No menses for 1 or more years or surgical menopause (bilateral oophorectomy). If there is a past history of hysterectomy, patient must be age 56 or older (95th percentile for age at menopause) or have laboratory evidence of menopause (ie. FSH >30)
  • Meets criteria for recurrent urinary tract infections (UTIs) with 2 or more UTI in 6 months or 3 or more UTI in 1 year
  • May include patients who used vaginal estrogen previously if they have stopped use for 3 or more months prior to inclusion into study.
  • Patients must be recommended vaginal estrogen as part of normal clinical care for prevention of recurrent UTI

Exclusion Criteria:

  • Current use of vaginal or oral estrogen products
  • Inability or refusal to use vaginal estrogen
  • Daily antibiotic use
  • Significant vaginal stenosis (eg. due to lichen sclerosis, radiation or obliterative prolapse surgery) that would prohibit use of a vaginal applicator (ie. genital hiatus <1cm)
  • Inability to use vaginal applicator and without caregiver who can administer (eg. provider-managed pessary use, significant arthritis)
  • Frequent (1x weekly or more frequent) use of bladder instillations containing an antibiotic
  • Known hydronephrosis as a result of incomplete bladder emptying
  • Use of intermittent or indwelling urinary catheterization
  • Known bladder stones, mesh erosion into bladder, or foreign object in bladder
  • Unable to consent for self
  • Active treatment for an estrogen-dependent malignancy

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Intravaginal Estrogen Application

Intravaginal application of 1 gram estradiol cream at bedtime twice a week for 6 months

The control group will apply 1 gram estradiol cream intravaginally using an applicator.

实验性的:Periurethral Estrogen Application

Periurethral application of 0.5 gram estradiol cream at bedtime twice a week for 6 months

The experimental group will apply estradiol cream in a different location (periurethral) and at a smaller dose (0.5 gram) compared to the control group.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants Who Are UTI-free at 6 Months
大体时间:6 months

The primary outcome was the percentage of participants who were UTI-free at 6 months after study drug initiation.

6 months

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in Urinary Symptoms at 6 Months
大体时间:Baseline, 6 months

Questionnaire assessment of urinary symptoms and symptom distress (Urogenital Distress Inventory, Short Form), total score range 0-100 with higher numbers representing worse urinary symptoms

Baseline, 6 months
Change From Baseline in Sexual Function at 6 Months
大体时间:Baseline, 6 months

Questionnaire assessment of sexual function (Female Sexual Function Index-6) with scores ranging from 2 to 30, with 19 and below denoting sexual dysfunction.

Baseline, 6 months
Change From Baseline in Vaginal pH at 6 Months
大体时间:Baseline, 6 months

Assessment using pH strips during pelvic examination

Baseline, 6 months
Participant Experience With Study Drug
大体时间:6 months

Agreement with the statement: "I am satisfied with the estrogen cream." (Positive response of "agree" or "strongly agree" on 5-point Likert Scale)

6 months
Vaginal Maturation Value
大体时间:3 months

Vaginal maturation value at 3 months (score 0-100, higher values correlating with greater vaginal estrogenization)

3 months
Average Amount of Estrogen Used Per Tube
大体时间:6 months

Study drug tubes were weighed at baseline and then at follow-up visits (weight in grams) and the average amount of study drug used per tube was calculated.

6 months
Percentage of Participants With Lactobacillus Crispatus Positive Vaginal Specimens
大体时间:6 months

Lactobacillus crispatus is a species of Lactobacillus known to assist with UTI prevention through the maintenance of an acidic environment. It generally is elevated in the vagina in the presence of estrogen.

6 months
Percentage of Participants With E. Coli Positive Vaginal Specimens
大体时间:6 months

E. coli is a common uropathogen and thus was investigated in the pilot translational sub-aim of this research study.

6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Stephanie W Zuo, MD、University of Pittsburgh Medical Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年1月3日

初级完成 (实际的)

2025年6月15日

研究完成 (实际的)

2025年6月25日

研究注册日期

首次提交

2022年7月21日

首先提交符合 QC 标准的

2022年7月21日

首次发布 (实际的)

2022年7月25日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年8月31日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅